Home/Pipeline/M102

M102

Amyotrophic Lateral Sclerosis (ALS)

Phase 1Active

Key Facts

Indication

Amyotrophic Lateral Sclerosis (ALS)

Phase

Phase 1

Status

Active

Company

Aclipse Therapeutics

About Aclipse Therapeutics

Aclipse Therapeutics is a private, clinical-stage biotech founded in 2018 and headquartered in Durham, North Carolina. The company is transitioning from preclinical to clinical development with two lead small molecule candidates: M107, poised for a Phase 2 trial in gastroparesis, and M102, targeting a Phase 1 trial in ALS. Aclipse's strategy integrates drug development with patient stratification biomarker approaches to improve clinical outcomes, backed by a management team with a strong track record in drug development and business transactions.

View full company profile

Therapeutic Areas

Gastroenterology Neurology Neuromuscular

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

Drug	Company	Phase	Status
NPT520-34	Neuropore Therapies	Pre-clinical/Phase 1	Partnered (Biogen), Active
NUZ-001	Neurizon Therapeutics	Phase 2/3 (Platform Trial)	Active
CNM-Au8	Clene	Phase 2/3	Active
Masitinib	AB Science	Phase 3	Active
Undisclosed Program	Zhimeng Biopharma	Clinical	Active
SLS-005	Seelos Therapeutics	Platform Trial	Active (HEALEY ALS Platform Trial – Regimen E)
PMN442	ProMIS Neurosciences	Preclinical	Active
nAV-101	nVector	Pre-clinical	Active
ALTA-808	Alteron Therapeutics	Preclinical	IND-enabling studies launching
GM6	Genervon Biopharmaceuticals	Phase 2	Active
Lou Gehrig’s disease	Genclis	Discovery	Active
Treg-directed therapy for ALS	Iltoo Pharma	Pre-clinical	Active